NovoCure (NVCR) Cash & Equivalents Growth (3y) (2017 - 2026)
NovoCure (NVCR) Cash & Equivalents Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -36.69% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 40.99% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.11% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.52% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -0.70% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 28.25% |
| 10 | NovoCure | 1.63 Bn | 1.20 Bn | 135.13 Mn | -22.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21% |
| Dec 31, 2025 | -6.74% |
| Sep 30, 2025 | 11.96% |
| Jun 30, 2025 | -25.85% |
| Mar 31, 2025 | -12.61% |
| Dec 31, 2024 | -7.78% |
| Sep 30, 2024 | -35.46% |
| Jun 30, 2024 | -22.14% |
| Mar 31, 2024 | 12.99% |
| Dec 31, 2023 | 0.87% |
| Sep 30, 2023 | -12.91% |
| Jun 30, 2023 | -7.26% |
| Mar 31, 2023 | 0.74% |
| Dec 31, 2022 | -13.36% |
| Sep 30, 2022 | 5.43% |
| Jun 30, 2022 | 26.79% |
| Mar 31, 2022 | 7.85% |
| Dec 31, 2021 | 14.08% |
| Sep 30, 2021 | 77.69% |
| Jun 30, 2021 | 45.03% |